vs
TOOTSIE ROLL INDUSTRIES INC（TR）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
TOOTSIE ROLL INDUSTRIES INC的季度营收约是再鼎医药的1.5倍（$196.3M vs $127.1M），再鼎医药同比增速更快（17.1% vs 1.5%），TOOTSIE ROLL INDUSTRIES INC自由现金流更多（$61.0M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 13.2%）
图西罗工业是总部位于美国伊利诺伊州芝加哥的糖果生产企业，核心产品包括同名的图西罗软糖、图西棒棒糖等广受欢迎的糖果产品，旗下品牌目前已销往加拿大、墨西哥等全球超过75个国家和地区。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
TR vs ZLAB — 直观对比
营收规模更大
TR
是对方的1.5倍
$127.1M
营收增速更快
ZLAB
高出15.6%
1.5%
自由现金流更多
TR
多$87.7M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
13.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $196.3M | $127.1M |
| 净利润 | $28.8M | — |
| 毛利率 | 35.7% | 51.0% |
| 营业利润率 | 17.0% | -54.6% |
| 净利率 | 14.7% | — |
| 营收同比 | 1.5% | 17.1% |
| 净利润同比 | 27.9% | — |
| 每股收益（稀释后） | — | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收TRZLAB
| Q4 25 | $196.3M | $127.1M | ||
| Q3 25 | $232.7M | $115.4M | ||
| Q2 25 | $155.1M | $109.1M | ||
| Q1 25 | $148.5M | $105.7M | ||
| Q4 24 | $193.4M | $108.5M | ||
| Q3 24 | $225.9M | $101.8M | ||
| Q2 24 | $150.7M | $100.1M | ||
| Q1 24 | $153.2M | $87.1M |
净利润TRZLAB
| Q4 25 | $28.8M | — | ||
| Q3 25 | $35.7M | $-36.0M | ||
| Q2 25 | $17.5M | $-40.7M | ||
| Q1 25 | $18.1M | $-48.4M | ||
| Q4 24 | $22.5M | — | ||
| Q3 24 | $32.8M | $-41.7M | ||
| Q2 24 | $15.6M | $-80.3M | ||
| Q1 24 | $15.8M | $-53.5M |
毛利率TRZLAB
| Q4 25 | 35.7% | 51.0% | ||
| Q3 25 | 34.1% | 59.5% | ||
| Q2 25 | 36.4% | 60.6% | ||
| Q1 25 | 35.3% | 63.6% | ||
| Q4 24 | 39.1% | 61.5% | ||
| Q3 24 | 34.1% | 64.1% | ||
| Q2 24 | 33.5% | 64.9% | ||
| Q1 24 | 32.7% | 61.4% |
营业利润率TRZLAB
| Q4 25 | 17.0% | -54.6% | ||
| Q3 25 | 13.9% | -42.3% | ||
| Q2 25 | 7.8% | -50.3% | ||
| Q1 25 | 15.5% | -53.3% | ||
| Q4 24 | 20.0% | -62.6% | ||
| Q3 24 | 15.6% | -66.6% | ||
| Q2 24 | 10.2% | -76.0% | ||
| Q1 24 | 7.3% | -80.7% |
净利率TRZLAB
| Q4 25 | 14.7% | — | ||
| Q3 25 | 15.3% | -31.2% | ||
| Q2 25 | 11.3% | -37.3% | ||
| Q1 25 | 12.2% | -45.8% | ||
| Q4 24 | 11.6% | — | ||
| Q3 24 | 14.5% | -40.9% | ||
| Q2 24 | 10.4% | -80.2% | ||
| Q1 24 | 10.3% | -61.4% |
每股收益（稀释后）TRZLAB
| Q4 25 | — | $-0.05 | ||
| Q3 25 | — | $-0.03 | ||
| Q2 25 | — | $-0.04 | ||
| Q1 25 | — | $-0.04 | ||
| Q4 24 | — | $-0.09 | ||
| Q3 24 | — | $-0.04 | ||
| Q2 24 | — | $-0.08 | ||
| Q1 24 | — | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $176.6M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $941.0M | $715.5M |
| 总资产 | $1.3B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资TRZLAB
| Q4 25 | $176.6M | $689.6M | ||
| Q3 25 | $119.8M | $717.2M | ||
| Q2 25 | $170.5M | $732.2M | ||
| Q1 25 | $176.6M | $757.3M | ||
| Q4 24 | $194.6M | $779.7M | ||
| Q3 24 | $163.2M | $616.1M | ||
| Q2 24 | $131.2M | $630.0M | ||
| Q1 24 | $159.4M | $650.8M |
股东权益TRZLAB
| Q4 25 | $941.0M | $715.5M | ||
| Q3 25 | $918.9M | $759.9M | ||
| Q2 25 | $893.1M | $791.7M | ||
| Q1 25 | $879.4M | $810.8M | ||
| Q4 24 | $870.7M | $840.9M | ||
| Q3 24 | $870.2M | $667.7M | ||
| Q2 24 | $841.4M | $704.2M | ||
| Q1 24 | $834.4M | $762.2M |
总资产TRZLAB
| Q4 25 | $1.3B | $1.2B | ||
| Q3 25 | $1.2B | $1.2B | ||
| Q2 25 | $1.2B | $1.2B | ||
| Q1 25 | $1.1B | $1.2B | ||
| Q4 24 | $1.1B | $1.2B | ||
| Q3 24 | $1.1B | $985.3M | ||
| Q2 24 | $1.1B | $987.4M | ||
| Q1 24 | $1.1B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $73.3M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $61.0M | $-26.7M |
| 自由现金流率自由现金流/营收 | 31.1% | -21.0% |
| 资本支出强度资本支出/营收 | 6.3% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.55× | — |
| 过去12个月自由现金流最近4个季度 | $96.4M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流TRZLAB
| Q4 25 | $73.3M | $-26.0M | ||
| Q3 25 | $62.2M | $-32.0M | ||
| Q2 25 | $-8.5M | $-31.0M | ||
| Q1 25 | $3.6M | $-61.7M | ||
| Q4 24 | $68.8M | $-55.8M | ||
| Q3 24 | $61.3M | $-26.8M | ||
| Q2 24 | $-12.6M | $-42.2M | ||
| Q1 24 | $21.4M | $-90.1M |
自由现金流TRZLAB
| Q4 25 | $61.0M | $-26.7M | ||
| Q3 25 | $50.7M | $-35.0M | ||
| Q2 25 | $-16.0M | $-33.9M | ||
| Q1 25 | $750.0K | $-63.2M | ||
| Q4 24 | $64.7M | $-58.4M | ||
| Q3 24 | $55.8M | $-28.2M | ||
| Q2 24 | $-16.6M | $-42.9M | ||
| Q1 24 | $16.9M | $-91.1M |
自由现金流率TRZLAB
| Q4 25 | 31.1% | -21.0% | ||
| Q3 25 | 21.8% | -30.4% | ||
| Q2 25 | -10.3% | -31.1% | ||
| Q1 25 | 0.5% | -59.9% | ||
| Q4 24 | 33.5% | -53.8% | ||
| Q3 24 | 24.7% | -27.7% | ||
| Q2 24 | -11.0% | -42.9% | ||
| Q1 24 | 11.0% | -104.5% |
资本支出强度TRZLAB
| Q4 25 | 6.3% | 0.5% | ||
| Q3 25 | 5.0% | 2.6% | ||
| Q2 25 | 4.8% | 2.6% | ||
| Q1 25 | 1.9% | 1.5% | ||
| Q4 24 | 2.1% | 2.4% | ||
| Q3 24 | 2.4% | 1.3% | ||
| Q2 24 | 2.6% | 0.7% | ||
| Q1 24 | 2.9% | 1.1% |
现金转化率TRZLAB
| Q4 25 | 2.55× | — | ||
| Q3 25 | 1.74× | — | ||
| Q2 25 | -0.49× | — | ||
| Q1 25 | 0.20× | — | ||
| Q4 24 | 3.06× | — | ||
| Q3 24 | 1.87× | — | ||
| Q2 24 | -0.81× | — | ||
| Q1 24 | 1.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
TR
| Products | $194.3M | 99% |
| Rental And Royalty | $1.9M | 1% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
